Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine.
Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine.
复制标题
DOI：
10.1016/j.jdcr.2022.04.021
复制
发表时间：
2022-06
影响因子：
--
通讯作者：
Gulati, Nicholas
中科院分区：
文献类型：
--
作者：
Han, Joseph;Russo, Gerardo;Stratman, Scott;Psomadakis, Corinna E;Rigo, Rachel;Owji, Shayan;Luu, Yen;Mubasher, Adnan;Gonzalez, Belen Rubio;Ungar, Jonathan;Harp, Joanna;Magro, Cynthia;Ungar, Benjamin;Lamb, Angela;Gulati, Nicholas
线状伊加大疱性皮肤病（LABD）可以是特发性的或药物诱导的。它是一种自身免疫性起泡性疾病，其特征是伊加抗体沿真皮表皮连接处沿着线性沉积。药物诱导的线性伊加疾病（DILAD）在成人中更常见，比特发性LABD更严重，很少模仿中毒性表皮坏死松解症（TEN）伴阳性Nikolsky征和大疱。1、2 DILAD通常发生在激发药物首次给药后1 - 15天内，并在停药后2周内消退。尽管万古霉素是最常报告的与DILAD相关的药物，但其他药物（如胺碘酮、双氯芬酸、卡托普利、萘普生和苯妥英）也与DILAD相关。3尽管与DILAD有关的诱发药物清单很广泛，但尚未有任何DILAD与特比萘芬使用相关的报告。我们报告了一例86岁女性患者，在口服特比萘芬和最近接种第三剂Moderna COVID-19疫苗的情况下发生了TEN样DILAD。
Linear IgA bullous dermatosis (LABD) can be idiopathic or drug-induced. It is an autoimmune blistering disorder characterized by linear deposition of IgA antibodies along the dermoepidermal junction. Drug-induced linear IgA disease (DILAD) occurs more commonly in adults and is more severe than idiopathic LABD, rarely mimicking toxic epidermal necrolysis (TEN) with positive Nikolsky sign and large bullae. 1, 2 DILAD typically occurs within 1 to 15 days of the first dose of the inciting medication and resolves within 2 weeks of its discontinuation. Although vancomycin is the most commonly reported drug associated with DILAD, other drugs, such as amiodarone, diclofenac, captopril, naproxen, and phenytoin, have been associated with DILAD. 3 Although the list of inciting medications that have been implicated in DILAD is extensive, there have yet to be any reports of DILAD associated with the use of terbinafine. We report the case of an 86-year-old woman, who developed TEN-like DILAD in the setting of oral terbinafine and recent administration of the third dose of the Moderna COVID-19 vaccine.